STOCK TITAN

Kairos Pharma to Present at the LD Micro Main Event XVII

(Moderate)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Tags
conferences

Kairos Pharma (NYSE American: KAPA), a clinical-stage biopharmaceutical company, has announced its participation in the LD Micro Main Event XVII. The event is scheduled for October 28-30, 2024 at the Luxe Sunset Boulevard Hotel in Los Angeles.

Dr. John S. Yu, Chief Executive Officer of Kairos Pharma, will deliver a corporate overview during the conference. His presentation is set for Wednesday, October 30, 2024, at 12:00 PM PT.

Interested parties can register to watch the presentation online through the provided link: https://me24.sequireevents.com/

Loading...
Loading translation...
Argus Session date unavailable
-3.33% session move Open Argus
Details

News Market Reaction – KAPA

The recorded move for KAPA in the trading session of this news was -3.33%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

LOS ANGELES, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company, announced today that John S. Yu, M.D., Chief Executive Officer, will present a corporate overview at the LD Micro Main Event XVII. The conference is being held on October 28 – 30, 2024 at the Luxe Sunset Boulevard Hotel in Los Angeles.

Event:LD Micro Main Event XVII
Presentation Date:Wednesday, October 30, 2024
Time:12:00 PM PT
Register to watch presentation:https://me24.sequireevents.com/
  

About Kairos Pharma Ltd.

Based in Los Angeles, California, Kairos Pharma Ltd. (NYSE American: KAPA) is at the forefront of oncology therapeutics, utilizing structural biology to overcome drug resistance and immune suppression in cancer. Our lead candidate, ENV105, is an antibody that targets CD105—a protein identified as a key driver of resistance to various cancer treatments. Elevation of CD105 in response to standard therapy results in resistance and disease relapse. ENV105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV105 is in a Phase 2 clinical trial for castrate resistant prostate cancer and a Phase 1 trial for lung cancer, addressing significant unmet medical needs. For more information, visit kairospharma.com.

CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS

This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. You can identify forward-looking statements as those that are not historical in nature, particularly those that use terminology such as “may,” “should,” “expects,” “anticipates,” “contemplates,” “estimates,” “believes,” “plans,” “projected,” “predicts,” “potential” or “hopes” or the negative of these or similar terms. The reader is cautioned not to rely on these forward-looking statements. If underlying assumptions prove inaccurate, or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Kairos Pharma. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Such forward-looking statements relate to future events or our future performance. In evaluating these forward-looking statements, you should consider various factors, including: our expectations regarding the success and/or completion of our Phase 1 and Phase 2 clinical trials; our success in completing newly initiated clinical trials, commence new trials, and obtain regulatory approval following the conclusion of such trials; challenges and uncertainties inherent in product research and development; and the uncertainty regarding future commercial success. These and other factors may cause our actual results to differ materially from any forward-looking statement. Forward-looking statements are only predictions. The forward-looking statements discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us, including those described in Kairos Pharma’s prospectus filed with the SEC. We are not obligated to publicly update or revise any forward-looking statement, and Kairos Pharma is not required to update any forward-looking statement as a result of new information or future events or developments, except as required by U.S. federal securities laws.

Contact:

CORE IR
Louie Toma
investors@kairospharma.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When is Kairos Pharma (KAPA) presenting at the LD Micro Main Event XVII?

Kairos Pharma (KAPA) is presenting at the LD Micro Main Event XVII on Wednesday, October 30, 2024, at 12:00 PM PT.

Where is the LD Micro Main Event XVII being held?

The LD Micro Main Event XVII is being held at the Luxe Sunset Boulevard Hotel in Los Angeles from October 28-30, 2024.

Who will be presenting for Kairos Pharma (KAPA) at the LD Micro Main Event XVII?

Dr. John S. Yu, Chief Executive Officer of Kairos Pharma (KAPA), will be presenting a corporate overview at the event.

How can I watch Kairos Pharma's (KAPA) presentation at the LD Micro Main Event XVII?

You can register to watch the presentation online through the link provided: https://me24.sequireevents.com/

What type of company is Kairos Pharma (KAPA)?

Kairos Pharma (KAPA) is described as a clinical-stage biopharmaceutical company.

Keep reading